Currently does not include estimates of number of people who may need PrEP (e.g. number of IDUs at high risk of HIV acquisition) or TasP • Borrows average usage forecast from currently available forecasts till 2018 • Borrows epidemiological estimates from available estimates till 2018 • Assumptions: – Linear ...

Background: Extent and timing of public health usage of ARVs, especially new drugs, was a key area for the MPP to understand when we commenced our licensing work with originator and generic companies • MPP started its forecasting exercise in 2011, including all ARVs but focusing on ...

The purpose of this working paper is to revise and update the antiretroviral (ARV) priorities of the Medicines Patent Pool (MPP) taking into consideration recent developments in the clinical, market and intellectual property landscape for different ARVs. As part of its mandate, MPP assigns greater ...